


## NRG GY004 (NCT02446600) Olaparib vs Olaparib-Cediranib vs PCT



(US, Canada, Japan, Korea)

- Recurrent HGSC with PFI > 6 months (following most recent platinum)
- No more than 3 prior regimens (including primary therapy)
- RECIST measurable or evaluable disease with accessible tumor
- No prior PARPi therapy, prior bevacizumab permitted
- Stratify for BRCA status, number of prior treatment regimens
- Primary endpoint: PFS 85% Power with HR 0.625




\*Carboplatin + gemcitabine or paclitaxel or PLD

Open: FEB 2016  
Status: Ongoing Accrual  
Target: 550 pts (135 BRCA1/2 +)  
Notes: Anticipate closure NOV2017



**NRG GY005 (NCT02502266)**

**Olaparib-Cediranib vs PCT**



(US, Canada)

- Recurrent HGSC with PFI < 6 months (following most recent platinum)
- No more than 2 prior regimens (including primary therapy)
- RECIST measurable or evaluable disease, biopsy accessible
- No prior PARPi therapy, prior bevacizumab permitted
- Stratify for BRCA status, number of prior treatment regimens
- Primary endpoint: OS 90% Power with HR 0.62



Open: FEB 2016  
 Status: Suspended for phase II interim analysis  
 Target: 460 pts (135 BRCA1/2 +)  
 Notes: Anticipate re-activation MAY2018


**NRG GY009 (NCT02839707)**

**PLD +/- Bevacizumab +/- Atezolizumab**

(US PIWG)



- Recurrent high-grade with PFI < 6 months (following most recent platinum)
- No more than 2 prior regimens (including primary therapy)
- RECIST measurable or evaluable disease with accessible tumor
- No prior anti-angiogenic therapy for platinum-resistant recurrence
- Primary endpoints: Phase II PFS (selective) → Phase III OS



HR PFS ≤ 0.783 (88% power)  
 HR OS\* ≤ 0.625 (90% power)  
 \*one-tail α 0.0115  
 (multiple comparisons)

Open: MAY 2017  
 Status: Ongoing safety lead-in (Phase I Working Group)  
 Target: 272 Phase II, Cumulative 488 Phase III  
 Notes: Anticipate Group-wide activation JAN2018